RenovoRx Inc (RNXT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RenovoRx Inc (RNXT) has a cash flow conversion efficiency ratio of -0.281x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.27 Million) by net assets ($8.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RenovoRx Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how RenovoRx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of RenovoRx Inc for a breakdown of total debt and financial obligations.
RenovoRx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RenovoRx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inoviq Ltd
AU:IIQ
|
-0.098x |
|
HOYA Resort Hotel Group
TWO:2736
|
-0.014x |
|
Sakuma Exports Limited
NSE:SAKUMA
|
0.171x |
|
Australian Gold and Copper Ltd
AU:AGC
|
-0.013x |
|
Elektrocieplownia Bedzin
WAR:BDZ
|
0.159x |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
-0.818x |
|
Deliveroo Holdings PLC
LSE:ROO
|
0.239x |
|
Aurora Mobile Ltd
NASDAQ:JG
|
0.048x |
Annual Cash Flow Conversion Efficiency for RenovoRx Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of RenovoRx Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see RenovoRx Inc (RNXT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.48 Million | $-9.12 Million | -2.038x | -159.59% |
| 2023-12-31 | $-3.00 Million | $-10.26 Million | 3.419x | +339.17% |
| 2022-12-31 | $6.16 Million | $-8.81 Million | -1.430x | -270.92% |
| 2021-12-31 | $15.35 Million | $-5.92 Million | -0.385x | -260.12% |
| 2020-12-31 | $-14.66 Million | $-3.53 Million | 0.241x | +110.53% |
| 2019-12-31 | $1.47 Million | $-3.35 Million | -2.287x | -- |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was… Read more